SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) Chairman Jurgi Camblong sold 8,500 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $7.61, for a total transaction of $64,685.00. Following the sale, the chairman directly owned 3,444,322 shares in the company, valued at $26,211,290.42. This trade represents a 0.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jurgi Camblong also recently made the following trade(s):
- On Friday, August 7th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.23, for a total value of $144,600.00.
- On Tuesday, August 4th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total value of $138,400.00.
- On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.63, for a total value of $132,600.00.
- On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.29, for a total value of $153,356.49.
- On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.62, for a total value of $47,770.00.
- On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total transaction of $93,376.80.
- On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.25, for a total transaction of $118,051.50.
- On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $7,826.10.
- On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.80, for a total transaction of $290,400.20.
- On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.24, for a total transaction of $44,540.00.
SOPHiA GENETICS Stock Performance
SOPH stock traded down $0.04 during trading on Monday, hitting $7.67. 408,022 shares of the company traded hands, compared to its average volume of 221,806. The company has a market cap of $643.44 million, a PE ratio of -6.67 and a beta of 0.96. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The stock's 50-day simple moving average is $5.63 and its 200 day simple moving average is $5.15. SOPHiA GENETICS SA has a 1 year low of $2.96 and a 1 year high of $7.88.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. On average, equities analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.
Hedge Funds Weigh In On SOPHiA GENETICS
Institutional investors and hedge funds have recently made changes to their positions in the stock. Perkins Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS in the 4th quarter valued at about $49,000. Squarepoint Ops LLC purchased a new stake in SOPHiA GENETICS during the third quarter worth approximately $49,000. First Dallas Securities Inc. acquired a new position in SOPHiA GENETICS in the first quarter valued at approximately $50,000. Quadrature Capital Ltd acquired a new position in SOPHiA GENETICS in the fourth quarter valued at approximately $54,000. Finally, XTX Topco Ltd purchased a new position in SOPHiA GENETICS in the fourth quarter valued at approximately $55,000. 31.59% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on SOPH shares. Zacks Research upgraded SOPHiA GENETICS to a "hold" rating in a report on Tuesday, July 21st. Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. HC Wainwright lifted their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Finally, BTIG Research boosted their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $10.00.
Check Out Our Latest Report on SOPH
About SOPHiA GENETICS
(
Get Free Report)
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider SOPHiA GENETICS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SOPHiA GENETICS wasn't on the list.
While SOPHiA GENETICS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
